London‑listed Advanced Medical Solutions (AMS) has attracted interest from private‑equity firm TA Associates, which is reportedly negotiating to take the company private. AMS specialises in tissue‑healing devices, including adhesives, sutures, haemostats and internal fixation tools used in surgery. The deal would shift AMS from a public to a private ownership structure, potentially unlocking new growth avenues for investors, staff, and partners.

TA Associates would need to formalise its intent by May 16, according to the source. If the bid succeeds, AMS would no longer trade on the London Stock Exchange, allowing the private‑equity firm to streamline operations and pursue long‑term R&D investments without shareholder scrutiny. The move could also signal a broader trend of consolidation in the medical‑device sector for investors, and analysts.

Market watchers will scrutinise the valuation terms once disclosed, as private‑equity buyouts can reshape competitive dynamics. AMS’s portfolio of tissue‑healing technologies positions it well for the growing demand for minimally invasive procedures. A successful transition could accelerate product roll‑outs and strengthen its bargaining power with hospitals and distributors for delivery and cost reductions across the healthcare sector in next years.